- Home
- VRCA vs FBRX Comparison
VRCA vs FBRX Comparison
Compare VRCA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | FBRX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 253.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | FBRX |
|---|---|---|
| Price | $8.00 | $21.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 399.9K | 113.8K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $4.90 |
| 52 Week High | $9.82 | $25.97 |
Technical Indicators
Market Signals| Indicator | VRCA | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 64.32 |
| Support Level | $7.82 | $18.85 |
| Resistance Level | $9.78 | $21.45 |
| Average True Range (ATR) | 1.18 | 2.00 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 64.93 | 66.30 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).